Abstract
Vinpocetine is a widely used drug for the treatment of cerebrovascular and memory disorders. This study aimed to investigate the effect of vinpocetine on the acute hepatic injury caused in the rat by the administration of CCl4in vivo. Vinpocetine (2.1, 4.2, 8.4 mg/kg) or silymarin (30 mg/kg) was given once daily orally simultaneously with CCl4 and for 15 days thereafter. Liver damage was assessed by determining serum enzyme activities and hepatic histopathology. Stained sections were subjected to morphometric evaluation using computerized image analyzer. The results showed that vinpocetine administered to CCl4-treated rats decreased the elevated alanine aminotransferase (ALT) by 49.3, 58.1 and 63.6%, aspartate aminotransferase (AST) by 10.5, 22.6 and 27.2% and alkaline phosphatase (ALP) by 52.5, 59.6 and 64.9%, respectively, and in a dose-dependent manner. Meanwhile, silymarin reduced elevated ALT, AST and ALP levels by 53.1, 26.9 and 66%, respectively. Histological examination of liver specimens revealed a marked reduction in liver cell necrosis in vinpocetine and silymarin-treated rats compared with vehicle-treated CCl4-treated rats. Quantitative analysis of the area of damage showed 85.3% reduction in the area of damage after silymarin and 72.2, 78.9 and 82.6% reduction after vinpocetine treatment at 2.1, 4.2, 8.4 mg/kg, respectively. It is concluded that administration of vinpocetine in a model of CCl4-induced liver injury in rats reduced liver damage. The reduction obtained by 4.2 mg/kg of vinpocetine was similar to that obtained by 30 mg/kg silymarin. Therefore, it is suggested that vinpocetine might be a good pharmacological agent in the treatment of liver disease besides its neuroprotective effects.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Arif, A., Levine, R. A., Sanderson, S. O., Bank, L., Velu, R. P., Shah, A., Mahl, T. C., Gregory, D. H. (2003) Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig. Dis. Sci. 48, 1425–1430.
Bacon, B. R. (2004) Managing hepatitis C. Am. J. Manag. Care 10, S30-S40.
Bauer, J. D. (1982) Clinical Laboratory Methods. The C. V. Mosby Co., St. Louis, Toronto, London.
Bedossa, R. (1999) Natural history of liver fibrosis. Adv. Liver. Pathol. 32, 292–293.
Belfield, A., Goldberg, D. M. (1971) Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme 12, 561–573.
Bonoczk, P., Gulyas, B., Adam-Vizi, V., Nemes, A., Karpati, E., Kiss, B., Kapas, M., Szantay, C., Koncz, I., Zelles, T., Vas, A. (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 53, 245–254.
Crowley, L. V. (1967) The Reitman-Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin. Chem. 13, 482–487.
Farghali, H., Kamenikova, L., Hynie, S., Kmonickova, E. (2000) Silymarin effects on intracellular calcuim and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol. Res. 41, 231–237.
Flora, K., Hahn, M., Rosen, H., Benner, K. (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 93, 139–143.
Fried, M. W. (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36, S237–S244.
Hadjiev, D. (2003) Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyógy. Szemle 56, 166–172.
Hsu, C. T., Schichijo, K., Ito, M., Sekine, I. (1993) The effect of chemical sympathectomy on acute liver injury induced by carbon tetrachloride in spontaneously hypertensive rats. J. Auton. Nerv. Syst. 43, 91–96.
Kiss, B., Karpati, E. (1996) A blockade of Na (+) channels can prevent some of the mechanisms involved in CCl4 induced hepatotoxicity. Acta Pharm. Hung. 66, 213–224.
Landon, E. J., Naukam, R. J., Rama-Sastry, B. V. (1986) Effects of calcium channel blocking agents on calcium and centrilobular necrosis in the liver of rats treated with hepatotoxic agents. Biochem. Pharmacol. 35, 697–705.
Lillestll, I. K., Helle, K. B., Aardal, S. (1998) Relaxing effects of cyclic GMP and cyclic AMP-enhancing agents on the long-lasting contraction to endothelin-1 in the porcine coronary artery. Scand. J. Clin. Lab. Invest. 58, 625–634.
Maher, J. J. (2001) Interactions between hepatic stellate cells and the immune system. Semin. Liver Dis. 21, 417–426.
Manns, M. P., McHutchison, J. G., Gordon, S. C. et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958–965.
Marcellin, P., Asselah, T., Boyer, N. (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36, S47-56.
McCaughan, G. W., George, J. (2004) Fibrosis progression in chronic hepatitis C virus infection. Gut 53, 318–321.
Muriel, P., Mourelle, M. (1990) Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J. Appl. Toxicol. 10, 275–279.
Nekrassov, V., Sitges, M. (2000) Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain. Res. 868, 222–229.
Paget, G. E., Barnes, J. M. (1964) In: Laurence, D. R., Bacharach, A. L. (eds) Evaluation of Drug Activities Pharmacometics. Academic Press, London & NewYork, pp. 1–135.
Pianko, S., McHutchison, J. G. (2000) Treatment of hepatitis C with interferon and ribavirin. J. Gastroenterol. Hepatol. 15, 581–586.
Romero, G., Lasheras, B., Sainz-Suberviola, L., Cenarruzabeitia, E. (1994) Protective effects of calcium channel blockers in carbon tetrachloride-induced liver toxicity. Life Sci. 55, 981–990.
Sippel, H., Stauffert, I., Estler, C. J. (1993) Protective effect of various calcium antagonists against an experimentally induced calcium overload in isolated hepatocytes. Biochem. Pharmacol. 46, 1937–1944.
Sitges, M., Galvan, E., Nekrassov, V. (2005) Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem. Int. 46, 533–540.
Tanaka, N., Tanaka, K., Nagashima, Y., Kondo, M., Sekihara, H. (1999) Nitric oxide increases hepatic arterial blood flow in rats with carbon tetrachloride-induced acute hepatic injury. Gastroenterology 117, 173–180.
Szakács, T., Veres, Zs., Vereczkey, L. (2001) In vitro-in vivo correlation of the pharmakokinetics of vinpocetine. Pol. J. Pharmacol. 53, 623–628.
Vas, A., Gulyas, B., Szabo, Z., Bonoczk, P., Csiba, L., Kiss, B., Karpati, E., Panczel, G., Nagy, Z. (2002) Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J. Neurol. Sci. 203–204, 259–262.
Wellington, K., Jarvis, B. (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15, 465–489.
Wu, S. N. (2003) Large-conductance Ca2+-activated K+ channels: physiological role and pharmacology. Curr. Med. Chem. 10, 649–661.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Abdel Salam, O.M.E., Oraby, F.H. & Hassan, N.S. Vinpocetine Ameliorates Acute Hepatic Damage Caused by Administration of Carbon Tetrachloride in Rats. BIOLOGIA FUTURA 58, 411–419 (2007). https://doi.org/10.1556/ABiol.58.2007.4.8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1556/ABiol.58.2007.4.8